ACCEPTUSE OF COOKIES: To give you the best possible experience, this website uses cookies.
By continuing to use our website you are giving your consent to cookies being used. Cookies Policy
Based in Barcelona, Sagetis Biotech is a start-up company founded in 2010 as a spin-off of the GEMAT research group, led by Dr. Salvador Borrós, at the Institut Químic de Sarrià (IQS). Salvador has more than 110 peer review papers published in international journals, 3 book chapters and a text book in Inorganic Chemistry. He has also 17 patents, some of which are highly relevant for the areas of research at Sagetis.
Sagetis has developed NanoGene, an innovative delivery technology based on oligopeptide-modified Poly (β-amino) esters (OM-PBAEs) that enable the full potential of gene therapy. Thanks to NanoGene, plasmid DNA, ssDNA oligonucleotides, mRNA, siRNA, miRNA can be successfully formulated into nanoparticles showing potential advantages in terms of efficacy and safety (transduction/transfection rate, immunogenicity, pharmacokinetics, tumour tropism and liver de-targeting) over existing technologies.
Sagetis Biotech is always willing to share information about NanoGene technology with potential partners with expertise in gene therapy field and explore every licensing opportunity or collaboration.
Please, do not hesitate to contact us.
Eduard Diviu, BD and Eng.
CEO, Co-founder and Chairman of the Board at Sagetis Biotech.
With a business and engineering background, a marked entrepreneurial profile and a hands-on, science driven approach with a global view, Eduard has played a key role in the successful rise of capital since the company foundation. Eduard is also involved in the negotiations with Pharma companies and the establishment of IP strategies. He is skilful in management, human resources and setting up and executing strategic plans.
Salvador Borrós, PhD.
CSO, Co-founder and member of the Board at Sagetis Biotech. Full Professor at IQS. PhD in Chemical Engineering. Scientific Leader of Material Engineering Group (GEMAT). Member of the IQS's Bioengineering Department.
Vast and proven experience, amongst others, in Materials Science (Chemistry and Chemical Engineering), Materials Science Fundamentals (Industrial Engineering), Materials Technology (Industrial Engineering), Materials Selection, Polymeric and Ceramics Materials, Biomaterials and Medical Devices (where he also holds a Master in Bioengineering).
Noteworthy, he has robust knowledge and experience in Biomaterials (Stimuli sensitive polymeric nanoparticles for drug delivery; Design of biomimetic surfaces with both chemical and mechanical signalling) and Smart surfaces (Design and rapid manufacturing fabrication of scaffolds for bone and cartilage regeneration). Salvador is a cornerstone in the development and of Sagetis technology platform and the generation of intellectual property around it. He has over 110 publications and 17 patents and is in charge of the research activities carried out at Sagetis.
Xavier Rivero, BSc
COO and partner at Sagetis Biotech.
Seasoned professional with more than 30 years in the pharmaceutical industry, in particular in R&D and business development.
Driven by passion for differentiated, innovative products that cover unmet needs. Xavier is in charge of the Development activities carried out by the company in coordination with CROs and CMOs. He has designed the Development activities that have been key for obtaining Venture Capital for the company. Xavier has been also a key figure to assess the potential risks and solutions to transform Sagetis technologies into feasible products.
Anna Cascante, PhD
Head of Molecular and Cellular Biology/Head of Laboratory.
PhD in Biochemistry and Molecular Biology with extensive experience in gene therapy strategies and oncology through her experience in several postdoc positions. With a pharmaceutics background and a pragmatic, down to earth approach, Anna is also the head of laboratory and a key person in the transition of the R&D candidates into formulations that can be eventually turned into medicines for human use. Anna has also several peer reviewed publications and patents.
Josep Lamarca, MD
Business Development and partner at Sagetis Biotech
MD in Neuropathology. Seasoned executive with a broad background in business development including in and out-licensing transactions. Josep has a proven track record of in and out licensing deals in both US, Japan and Europe and has a vast experience of interaction with pharma, biotech and drug delivery technology companies worldwide. Josep has also established long term relationship with pharma companies in Japan and built up partnerships with leading multidisciplinary teams in the partnering process.
Besides, he has wide experience in different types of deals, from early-stage projects to commercial products, also supervising the Quality of secondary agreements. Josep has a vast experience in the preparation of in- and out-licensing strategies, and setting up internal protocols for project evaluation. He has participated as member of corporate staff, in the corporate strategic plan of a multinational pharmaceutical company. Prior to his experience in the industry, he conducted medical practice, medical education and biomedical research in neurobiology leading to original publications in the US and EU.
Caixa Capital Risc
VC firm of "la Caixa" that invests in early stage Spanish companies led by committed teams that have the potential for high growth.
Red de Inversores Privados y Family Offices
Investor’s Network made up of executives, business leaders, family offices, and other people and organizations with entrepreneurial drive that are interested in investing in new companies or businesses with the potential for growth. 4 members of this Network have invested in Sagetis Biotech.
CDTI. Iniciativa NEOTEC
The Centre for Industrial Technological Development (CDTI) is a Public Business Entity, answering to the Ministry of Economy and Competitiveness, which fosters the technological development and innovation of Spanish companies.
CDTI is supporting Sagetis Biotech through different instruments: NEOTEC, INNTERNACIONALIZA and PID.
Empresa Nacional de Innovación S.A. (ENISA)
ENISA aims to provide small and medium enterprises with financial instruments and long term funding formulas enabling them to strengthen their financial structures.
Seventh Framework Programme (EU)
The Seventh Framework Programme (FP7) bundles all research-related EU initiatives together under a common roof playing a crucial role in reaching the goals and growth, competitiveness and employment; along with a new Competitiveness and Innovation Framework Programme (CIP), Education and Training programmes, and Structural and Cohesion Funds for regional convergence and competitiveness.
Sagetis Biotech is currently participating in two FP7 projects: ALEXANDER and RESTORATION.
Ministerio de Economía y Competitividad (MINECO)
Sagetis Biotech has been granted funding from the following instruments: INNPACTO 2012, Subprograma INNCORPORA FPGS, INNCORPORA TORRES QUEVEDO, RETOS COLABORACIÓN 2014 AND RETOS DE COLABORACIÓN 2015.
Agència per a la competitivitat de l'empresa (ACCIÓ)
Sagetis Biotech has been granted funding from the ACCIÓ under the program NUCLIS DE RECERCA INDUSTRIAL I DESENVOLUPAMENT EXPERIMENTAL in 2015. The projects has been co-financed with FEDER funds.